Payment overview · 2025
General Payments
$1,515.32
73 reported records · 21 companies
Healthcare provider profile · identity verified
Mark A Bonner, MD
Allopathic & Osteopathic Physicians|Family Medicine · FAYETTEVILLE, AR · NPI 1437188869
Verified facts
What the public records show
CMS Open Payments records show Mark A Bonner, MD received $1,515.32 in general payments during 2025 across 73 reported records.
ABBVIE INC. accounted for 17.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $268.68 | 17.7% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $254.17 | 16.8% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $172.15 | 11.4% | 11 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $142.79 | 9.4% | 6 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $118.85 | 7.8% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $76.91 | 5.1% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $67.82 | 4.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $58.32 | 3.9% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $54.23 | 3.6% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $45.83 | 3.0% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $38.15 | 2.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.27 | 2.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.59 | 1.9% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $28.15 | 1.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.17 | 1.6% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $21.89 | 1.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.20 | 1.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.97 | 1.1% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $16.96 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.63 | 1.0% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $13.59 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,515.32 | 73 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $268.68 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $175.18 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $173.88 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $172.15 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $164.15 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $142.79 | 6 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $118.85 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $93.88 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $80.65 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $67.82 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $58.32 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $54.23 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $45.83 | 2 | 2025 |
Source payment records
|
|||||
| Sotyktu Normalized: sotyktu |
Drug | E.R. Squibb & Sons, L.L.C. | $38.15 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.59 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $28.15 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $10.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 152 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 47 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
152 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
88 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
163 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
152 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 861 | 171 |
| Atorvastatin Calcium | Atorvastatin Calcium | 749 | 167 |
| Lisinopril | Lisinopril | 533 | 134 |
| Omeprazole | Omeprazole | 511 | 105 |
| Losartan Potassium | Losartan Potassium | 461 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 452 | 106 |
| Pantoprazole Sodium | Pantoprazole Sodium | 416 | 90 |
| Gabapentin | Gabapentin | 407 | 96 |
| Potassium Chloride | Potassium Chloride | 404 | 81 |
| Metformin Hcl | Metformin Hcl | 398 | 100 |
| Trazodone Hcl | Trazodone Hcl | 377 | 71 |
| Meloxicam | Meloxicam | 334 | 67 |
| Furosemide | Furosemide | 296 | 63 |
| Alprazolam | Alprazolam | 286 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 277 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 259 | 74 |
| Glimepiride | Glimepiride | 248 | 60 |
| Allopurinol | Allopurinol | 246 | 42 |
| Montelukast Sodium | Montelukast Sodium | 238 | 50 |
| Sertraline Hcl | Sertraline Hcl | 238 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 232 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 218 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 212 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 199 | 45 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 197 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 192 | 45 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 191 | 41 |
| Liothyronine Sodium | Liothyronine Sodium | 184 | 33 |
| Terazosin Hcl | Terazosin Hcl | 176 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 163 | 103 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 163 | 35 |
| Ozempic | Semaglutide | 163 | 36 |
| Lorazepam | Lorazepam | 160 | 37 |
| Simvastatin | Simvastatin | 157 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 154 | 36 |
| Clonazepam | Clonazepam | 153 | 28 |
| Eliquis | Apixaban | 152 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 151 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 146 | 33 |
| Atenolol | Atenolol | 144 | 36 |
| Prednisone | Prednisone | 138 | 92 |
| Metoclopramide Hcl | Metoclopramide Hcl | 133 | 33 |
| Celecoxib | Celecoxib | 131 | 23 |
| Ezetimibe | Ezetimibe | 125 | 27 |
| Bupropion Xl | Bupropion Hcl | 124 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 121 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 46 |
| Propranolol Hcl | Propranolol Hcl | 118 | 20 |
| Tramadol Hcl | Tramadol Hcl | 116 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 21 |
| Pregabalin | Pregabalin | 113 | 20 |
| Diazepam | Diazepam | 112 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 112 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 112 | 25 |
| Azithromycin | Azithromycin | 110 | 68 |
| Estradiol | Estradiol | 108 | 28 |
| Spironolactone | Spironolactone | 106 | 23 |
| Warfarin Sodium | Warfarin Sodium | 106 | 16 |
| Famotidine | Famotidine | 102 | 24 |
| Clonidine Hcl | Clonidine Hcl | 99 | 28 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 98 | 18 |
| Ondansetron Odt | Ondansetron | 95 | 39 |
| Sucralfate | Sucralfate | 89 | 13 |
| Mounjaro | Tirzepatide | 88 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 81 | 15 |
| Temazepam | Temazepam | 81 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 19 |
| Topiramate | Topiramate | 80 | 19 |
| Metformin Hcl Er | Metformin Hcl | 78 | 21 |
| Cefdinir | Cefdinir | 76 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 24 |
| Sumatriptan Succinate | Sumatriptan Succinate | 74 | 15 |
| Carvedilol | Carvedilol | 73 | 20 |
| Fluconazole | Fluconazole | 71 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 67 | 30 |
| Cephalexin | Cephalexin | 66 | 43 |
| Gemfibrozil | Gemfibrozil | 66 | 17 |
| Ibandronate Sodium | Ibandronate Sodium | 64 | 14 |
| Glipizide | Glipizide | 62 | 15 |
| Amoxicillin | Amoxicillin | 60 | 31 |
| Buspirone Hcl | Buspirone Hcl | 60 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 36 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 59 | 30 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 57 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 55 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 54 | 11 |
| Synthroid | Levothyroxine Sodium | 54 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 52 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 51 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 29 |
| Finasteride | Finasteride | 49 | suppressed |
| Jardiance | Empagliflozin | 47 | 11 |
| Memantine Hcl | Memantine Hcl | 47 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 47 | suppressed |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Lamotrigine | Lamotrigine | 45 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 45 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 43 | 17 |
| Bumetanide | Bumetanide | 43 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 43 | 22 |
| Donepezil Hcl | Donepezil Hcl | 42 | suppressed |
| Ibuprofen | Ibuprofen | 41 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 40 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Carbamazepine | Carbamazepine | 39 | suppressed |
| Methocarbamol | Methocarbamol | 39 | 13 |
| Acyclovir | Acyclovir | 36 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 25 |
| Mupirocin | Mupirocin | 35 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 11 |
| Levofloxacin | Levofloxacin | 33 | 22 |
| Valacyclovir | Valacyclovir Hcl | 33 | 17 |
| Colchicine | Colchicine | 32 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | 12 |
| Prazosin Hcl | Prazosin Hcl | 32 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 32 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 23 |
| Trulicity | Dulaglutide | 29 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 27 | suppressed |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Etodolac | Etodolac | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 21 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Procto-Med Hc | Hydrocortisone | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Misoprostol | Misoprostol | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,515.32 · 73 records | ABBVIE INC. | ACCRUFER, AIRSUPRA, AREXVY, Auvelity, Azstarys, BREZTRI, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Jornay PM, NURTEC ODT, Ohtuvayre, Omnipod, QULIPTA, REXULTI, Sotyktu, TRELEGY ELLIPTA, UBRELVY, Veozah, Wegovy, ZAVZPRET | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error